Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HER2 cancer vaccine - BioLife Science

X
Drug Profile

HER2 cancer vaccine - BioLife Science

Alternative Names: Her VAXX; HER-Vaxx; IMU-131; PEV 6A; PEV6

Latest Information Update: 15 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioLife Science; Pevion Biotech
  • Developer Imugene; Pevion Biotech
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action ERBB 2 receptor antagonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • No development reported Breast cancer

Most Recent Events

  • 05 Apr 2024 Final efficacy and immunogenicity data from the phase-I/II HERIZON trial in Gastric cancer and Oesophageal cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 20 Oct 2023 Updated immunogenicity data from a phase I/II HERIZON trial on gastric cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 28 Jun 2023 Updated immunogenicity data from the phase Ib/II HERIZON trial in Gastric cancer presented at the 25th World Congress on Gastrointestinal Cancer (WCGC-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top